Matrix Medical Network Announces the Acquisition of Biocerna

Matrix Medical Network® (Matrix) today announced the acquisition of Biocerna, a CLIA-certified and CAP-accredited laboratory dedicated to delivering clinical diagnostics tests to improve patients’ safety and quality of care. Biocerna has developed innovative assays, including for COVID-19 testing, that will allow Matrix to provide safe and expedient testing services to Matrix Medical Network and Matrix Clinical Solutions clients. Biocerna is located in Fulton, Maryland and has significant experience in clinical diagnostics and clinical testing support for clinical trials.

“Matrix’s network of more than 3,000 clinicians and mobile health clinics brings health and safety assessments and solutions directly to individuals where they work and live,” said Matrix Chairman and Chief Executive Officer Keith Henthorne. “Adding the diagnostic and testing expertise of Biocerna to our in-house capabilities will allow us to provide even more timely support to our clients. Being able to quickly turn around critical test results is important, especially as we help our clients safely return employees to work and keep them working amidst the COVID-19 pandemic.”

Biocerna develops and commercializes non-invasive, readily accessible, easy-to-use and affordable diagnostics needed to accurately diagnose and treat health conditions. Biocerna currently processes a significant number of COVID-19 RT-PCR tests, is a leader in Alpha-1 Antitrypsin Deficiency testing, and offers various biometric screening tests including lipid panels, diabetes screening, and colorectal cancer screening.

“Biocerna takes great pride in the work we do as a high-quality diagnostic laboratory. Following the onset of the COVID-19 pandemic, we mobilized to handle COVID-19 testing in a timely and scalable manner,” said Biocerna Founder Chris Sanders. “I am excited to bring the amazing Biocerna team into the Matrix community in the coming months.”